Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Kosins

Psychiatry San Clemente, CA Medical Doctor

NPI 1457424954 CMS profile 338678

647 Camino De Los Mares, 226, San Clemente, CA 92673

Open in the dashboard

General payments

$4,754

268 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Kosins of San Clemente, CA is reported in the CMS Open Payments database as having received $4,754 across 268 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $330 15
2024 General $650 35
2023 General $883 47
2022 General $532 35
2021 General $895 52
2020 General $635 33
2019 General $829 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Kosins
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mark Kosins were reported at $330. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mark Kosins Psychiatry median Middle half National median
2019 $829 $184 $59–$605 $163
2020 $635 $119 $36–$372 $114
2021 $895 $143 $43–$576 $132
2022 $532 $153 $50–$590 $149
2023 $883 $170 $56–$651 $160
2024 $650 $179 $57–$673 $164
2025 $330 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,137 73 payments
  2. Lundbeck LLC $750 40 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $563 29 payments
  4. Allergan Inc. $375 30 payments
  5. Vanda Pharmaceuticals Inc. $374 17 payments
  6. Sunovion Pharmaceuticals Inc. $191 8 payments
  7. ITI, Inc. $188 8 payments
  8. Ironshore Pharmaceuticals Inc. $161 10 payments
  9. Almatica Pharma LLC $160 8 payments
  10. Alkermes, Inc. $147 8 payments
  11. Other $708 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,754 268 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $1,093 71 payments
  2. TRINTELLIX $431 23 payments
  3. REXULTI $426 21 payments
  4. VRAYLAR Neuroscience $419 32 payments
  5. FANAPT $374 17 payments
  6. BRINTELLIX $324 19 payments
  7. HETLIOZ $319 14 payments
  8. LATUDA $191 8 payments
  9. LOREEV XR $160 8 payments
  10. LYBALVI $147 8 payments
  11. Other $1,751 92 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

1,250

Median for Psychiatry & Neurology: 100

Drug cost

$119,731

Median for Psychiatry & Neurology: $2,986

Branded share of claims

25.7%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Caplyta Lumateperone Tosylate Brand 19 $43,477
Rexulti Brexpiprazole Brand 11 $16,533
Lisdexamfetamine Dimesylate Generic 36 $10,509
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 33 $5,563
Lurasidone Hcl Generic 29 $4,685
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 50 $4,450
Aripiprazole Generic 33 $4,099
Viibryd Vilazodone Hcl Brand 12 $3,961
Vilazodone Hcl Generic 19 $3,572
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 81 $2,917

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOREEV XR
  • Almatica Pharma LLC $160
$160 — —
VRAYLAR
  • AbbVie, Inc. $157
$157 — —
REXULTI
  • Lundbeck LLC $87
$87 11 —
QUVIVIQ
  • IDORSIA PHARMACEUTICALS US INC $80
$80 — —
CAPLYTA
  • ITI, Inc. $74
$74 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

268 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record